- Home
- PULM vs LEXX Comparison
PULM vs LEXX Comparison
Compare PULM & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- LEXX
- Stock Information
- Founded
- PULM 2003
- LEXX 2004
- Country
- PULM United States
- LEXX Canada
- Employees
- PULM N/A
- LEXX N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- LEXX Health Care
- Exchange
- PULM Nasdaq
- LEXX Nasdaq
- Market Cap
- PULM 20.5M
- LEXX 16.5M
- IPO Year
- PULM N/A
- LEXX N/A
- Fundamental
- Price
- PULM $4.87
- LEXX $1.03
- Analyst Decision
- PULM
- LEXX Strong Buy
- Analyst Count
- PULM 0
- LEXX 1
- Target Price
- PULM N/A
- LEXX $4.00
- AVG Volume (30 Days)
- PULM 11.0K
- LEXX 187.7K
- Earning Date
- PULM 08-06-2025
- LEXX 07-14-2025
- Dividend Yield
- PULM N/A
- LEXX N/A
- EPS Growth
- PULM N/A
- LEXX N/A
- EPS
- PULM N/A
- LEXX N/A
- Revenue
- PULM $369,000.00
- LEXX $615,923.00
- Revenue This Year
- PULM N/A
- LEXX $46.98
- Revenue Next Year
- PULM $134.88
- LEXX $17.26
- P/E Ratio
- PULM N/A
- LEXX N/A
- Revenue Growth
- PULM N/A
- LEXX 49.85
- 52 Week Low
- PULM $1.78
- LEXX $0.77
- 52 Week High
- PULM $10.40
- LEXX $3.72
- Technical
- Relative Strength Index (RSI)
- PULM 44.33
- LEXX 63.07
- Support Level
- PULM $4.65
- LEXX $0.86
- Resistance Level
- PULM $5.00
- LEXX $1.09
- Average True Range (ATR)
- PULM 0.16
- LEXX 0.08
- MACD
- PULM 0.06
- LEXX 0.02
- Stochastic Oscillator
- PULM 76.92
- LEXX 81.47
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.